CTIS.eu › Cities › Spain › Barcelona
Barcelona
Spain
3,391 total trials
1,343 recruiting
Filter these 3,391 trials by phase, condition, sponsor and more.
Open in Search →
2023-509343-27-00
11
2019-10-28
C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
2023-503433-21-00
5
2019-10-03
Behçet’s disease is a chronic, relapsing, multisystem inflammatory dis
2023-508689-14-00
5
2019-09-16
Sickle cell disease
2023-509179-18-00
1
2019-08-13
Castration Resistant Prostate Cancer (CRPC)
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
2024-513734-38-00
5
2019-07-03
Prevention of breast cancer in women with a BRCA1 germline mutation
2023-510424-68-00
9
2019-05-28
Advanced Solid Tumors
2024-515690-10-00
9
2019-05-10
Follicular B-cell non-Hodgkin's lymphoma
2023-508302-24-00
4
2019-05-07
Locally Advanced/Metastatic Urothelial Cancer
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
2024-512701-11-00
4
2018-08-29
Systemic Juvenile Idiopathic Arthritis (sJIA)
2022-501254-10-00
5
2018-08-24
Advanced tumors
2023-503629-20-00
9
2018-06-27
Metastatic breast cancer, including triple negative breast cancer (TNB
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
2024-513627-16-01
7
2018-03-28
Colorectal cancer metastatic
2024-514238-19-00
4
2018-03-28
Subjects with advanced solid tumour
2024-516110-38-00
5
2018-03-06
Hepatoblastoma and Hepatocellular Carcinoma
2023-509318-13-00
6
2018-01-15
Multiple indications
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
2023-504520-26-00
5
2017-10-19
Duchenne Muscular Dystrophy (DMD)
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
2023-510032-37-00
7
2017-04-18
Mucopolysaccharidosis type IIIA
2023-505625-14-00
7
2017-01-31
Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)
2023-506987-15-00
9
2016-11-17
Metastatic Castration-Resistant Prostate Cancer
Showing 1,585–1,608 of 3,391 trials